India amends fee structure, new form for import certificate introduced for NDPS; market forecasts

2 September 2010

The Department of Revenue, under India's Union Ministry of Finance, has revised and introduced a new fee structure for processing applications for manufacturing licence and import and export certificated for narcotic drugs and psychotropic substances through an amendment to the Narcotic Drugs & Psychotropic Substances (NDPS) Rules, 1985, reports the local PharmaBiz news service.

Through notifying the NDPS (Amendment) Rules, 2010, in July, the department has revised the fee for manufacturing license and renewal of manufacturing license for manufacture of synthetic narcotic drugs from Rs 50 to Rs 5000 per application.

The department has also introduced fee for issuance of import and exports of NDPS, through the amendment. According to this, Fee of Rs 1000 has been introduced per application for issuance of both import certificate for import of narcotic drugs and psychotropic substances and issuance of export authorization for export of the drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical